2型糖尿病合并房颤患者启动GLP-1RA后的出血与血栓栓塞结局:目标试验模拟
本研究采用目标试验模拟方法,在≥65岁接受DOAC的2型糖尿病合并房颤的Medicare受益人中比较启动GLP-1RA与DPP-4抑制剂的结局。倾向评分1:1匹配后每组930例,平均随访1年。GLP-1RA启动与出血风险升高(HR 1.18,95%CI 1.03–1.36)、全因死亡降低(HR 0.58,95%CI 0.36–0.95)相关,血栓栓塞风险无显著差异(HR 1.50,95%CI 0.22–10.43)。
要点
- GLP-1RA启动与出血风险升高相关(HR 1.18,95%CI 1.03–1.36)。
- GLP-1RA启动与全因死亡降低相关(HR 0.58,95%CI 0.36–0.95)。
- 血栓栓塞风险无显著差异(HR 1.50,95%CI 0.22–10.43)。
核心结论
- 在DOAC治疗的2型糖尿病合并房颤患者中,启动GLP-1RA与出血风险升高相关,但未观察到血栓栓塞风险明显增加。
研究设计与样本
- 采用目标试验模拟方法,比较GLP-1RA与DPP-4抑制剂启动,研究对象为≥65岁接受DOAC的2型糖尿病合并房颤Medicare受益人。
- 采用1:1倾向评分匹配,匹配后每组930例,平均随访1年。
- 采用逆概率删失加权Cox比例风险模型估计符合方案效应。
主要发现
- GLP-1RA组与DPP-4抑制剂组平均年龄分别为74.7岁与74.2岁,女性比例分别为47.1%与44.2%。
- GLP-1RA启动与出血风险升高相关(HR 1.18,95%CI 1.03–1.36)。
- GLP-1RA启动与全因死亡降低相关(HR 0.58,95%CI 0.36–0.95)。
- GLP-1RA启动与血栓栓塞风险无显著差异(HR 1.50,95%CI 0.22–10.43)。
临床怎么用
- 对接受DOAC的2型糖尿病合并房颤患者启动GLP-1RA时,应加强出血监测。
- 个体化治疗决策可考虑体重与肾功能等因素,但需进一步研究支持。
局限性
- 研究纳入≥65岁Medicare受益人,结论外推至其他人群需谨慎。
- 平均随访1年,长期结局未评估。
- 未纳入体重与肾功能等变量进行个体化分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims Patients with atrial fibrillation (AF) and Type 2 diabetes (T2D) require coordinated stroke prevention and metabolic risk management. Direct oral anticoagulants (DOACs) are standard for stroke prevention, while glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used in T2D. In DOAC users, GLP-1RA initiation may alter body weight and gastrointestinal physiology, potentially increasing DOAC exposure and thereby elevating bleeding risk. We aim to investigate the impact of GLP-1RA initiation on risks of thromboembolic disease and bleeding in patients with T2D and AF receiving DOACs. Materials and Methods We emulated a target trial comparing GLP-1RA versus dipeptidyl peptidase-4 (DPP-4) inhibitor initiation. We identified Medicare beneficiaries aged ≥ 65 years with T2D and AF receiving DOACs. Randomization was emulated using 1:1 propensity score matching. Primary outcomes include thromboembolic disease and bleeding. Per-protocol effects were estimated using inverse-probability-censoring-weighted Cox proportional hazards models. Results After matching, 930 patients were included in each group, with mean follow-up of 1 year. Mean age was 74.7 vs. 74.2 years, and 47.1% vs. 44.2% were women in the GLP-1RA vs. DPP-4 inhibitor groups. GLP-1RA initiation was associated with higher bleeding risk (HR 1.18, 95% CI: 1.03–1.36), lower all-cause mortality (HR 0.58, 95% CI: 0.36–0.95), and similar thromboembolic risk (HR 1.50, 95% CI: 0.22–10.43). Conclusions Among DOAC-treated patients with T2D and AF, GLP-1RA initiation was associated with a less favourable bleeding profile but no evident increase in thromboembolic risk. These findings support careful clinical monitoring and further studies incorporating body weight and renal function to inform individualized treatment.
引用
- Diabetes, Obesity and Metabolism:Bleeding and Thromboembolic Outcomes Following GLP‐1 Receptor Agonist Initiation in Patients With Type 2 Diabetes and Atrial Fibrillation Receiving Direct Oral Anticoagulants: A Target Trial Emulation
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。